Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics

NCT02169414 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease (PD)

Interventions

DRUG: BIA 9-1067 5 mg
DRUG: BIA 9-1067 25 mg
DRUG: levodopa/carbidopa 100/25
DRUG: Placebo
DRUG: levodopa/benserazide 100/25 mg

Sponsor

Bial - Portela C S.A.